Verastem To Present At The 2012 San Antonio Breast Cancer Symposium

Verastem, Inc., (NASDAQ: VSTM) a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the presentation of data at the CTRC-AACR San Antonio Breast Cancer Symposium on December 4-8, 2012, in San Antonio, Texas.

The details of the Verastem poster presentations are as follows:

Title: FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function in Vitro and in Vivo

Date: December 8, 2012, from 7:00 – 8:30 am CT

Session: Poster Session 6

Poster Number: P6-11-09

Location: Exhibit Hall C

Title: The Cancer Stem Cell-Targeting Wnt Inhibitor VS-507 Reduces Breast Cancer Growth and Metastasis

Date: December 8, 2012, from 7:00 – 8:30 am CT

Session: Poster Session 6

Poster Number: P6-11-07

Location: Exhibit Hall C

About Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

If you liked this article you might like

Verastem Shares Are Exploding 50% -- Here's Why

8 Breakout Stocks Under $10 to Trade for Big Profits

Verastem (VSTM) Stock Spiking on Q4 Results

7 Stocks Under $10 Making Big Breakout Moves

4 Stocks Under $10 Making Big Up Moves on Big Volume